Global
Our Story

Share the latest information

Our Story
News
2024-05-11
International Conference 及2024 BIO International Convention
Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun
More
2024-05-11
International Conference 及2024 BIO International Convention
Shanghai, China, May 11, 2024 - Shanghai Novamab Biopharmaceuticals Co., Ltd., a biotechnology company dedicated to the research and development of innovative nanobody drugs, announced that Dr. Yakun
More
2024-04-23
Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients
Shanghai, China, April 23, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced that its core product LQ036 (an IL-4Rα single-domain
More
2024-03-05
BioCon 2024- "Research Progress of Inhalable Nanobody Drug Therapy for Asthma" A Brief Discussion on Differentiated Development of Antibody Drugs and Clinical Progress of Novamab
Beijing time, March 6, 2024 (Wednesday), from 19:45 to 20:25, Dr. Siran Pei, the head of Translational Medicine and Clinical Development at Novamab, will participate in the pre-event live broadcast of
More
2024-02-29
Research Information - The development and scaling up of the production process of Novamab‘s anti TSLP Nanobody have reached an internationally leading level
Shanghai, February 29, 2024 - Novamab, a biotechnology company dedicated to the research and development of innovative Nanobody drugs, announced the research progress on the development and scaling up
More
2024-02-22
Clinical Research Updatate - Novamab Announced the Latest Results of the Phase Ia Clinical Study on Inhaled TSLP Nanobody Drug LQ043H in Healthy Chinese Subjects
Shanghai, February 22, 2024- Novamab, a biotechnology company dedicated to the research and development of innovative Nonobody drugs, announced today the results of the tolerance, safety, pharmacokine
More
2023-12-19
Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan
On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.
More
2023-11-13
The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!
Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p
More
2023-09-26
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference
More
2023-09-18
CDE approves IND application for LQ036 in the treatment of COPD
CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇
More
2023-07-04
CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum
CEO of Luoqi Biotechnology delivers a speech at the ACCESS CHINA Pharmaceuticals China Boston ForumA leading global enterprise in the research and development of innovative nano antibody drugsThe offl
More
Total 51 123456